Serum miR-26a-5p and miR-199b-5p as a biomarker to predict therapy for Diffuse Large B-cell lymphoma with Hepatitis C Infection

The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma

Clinicopathological Significance of A20 Genetic Mutation in Diffuse Large B-Cell Lymphoma

Study of high mobility group box 1 protein level in patients with diffuse large b cell lymphoma

The Association of Mean Platelet Volume and Red Cell Distribution Width with Disease Free Survival in Diffuse Large B Cell Lymphoma

Prognostic Significance of Concurrent MYC, BCL2 and/or BCL6 Expression in Diffuse Large B-Cell Lymphoma

Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Diffuse Large B Cell Lymphoma Patients Treated with RCHOP

Genetic Variants of MicroRNA-146a and MicroRNA-196a2 are Associated with Poor Outcome but not Risk of High-Grade B- Cell Non-Hodgkin Lymphoma

CLINICOPATHOLOGICAL AND PROGNOSTIC SIGNIFICANCE OF PLATELET TO LYMPHOCYTE RATIO IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS

Inverse correlation of concurrent BCL2, and C MYC expressions and CD30 ‎positivity as regard the Prognostic significance in diffuse large B-cell ‎lymphoma